Igbinoba S I, Akanmu M A, Onyeji C O, Soyinka J O, Owolabi A R, Nathaniel T I, Pullela S V, Cook J M
Department of Clinical Pharmacy and Pharmacy Administration, Obafemi Awolowo University, Ile-Ife, Nigeria.
Department of Pharmacology, Obafemi Awolowo University, Ile-Ife, Nigeria.
J Clin Pharm Ther. 2015 Oct;40(5):545-549. doi: 10.1111/jcpt.12303. Epub 2015 Jul 14.
Some studies, howbeit with conflicting reports, have suggested that consumption of honey has a potential to modulate drug metabolizing enzymes which may result in a honey-drug interaction. Numerous studies have established that honey varies in composition, influenced by the dominant floral, processing and environmental factors. Thus, variation in honey composition may be a contributing factor to the controversial results obtained. No previous drug interaction study has been carried out with any honey from Africa. CYP 3A4 is an important enzyme in drug metabolism studies as it is involved in the metabolism of over 50% of drugs in clinical use and quinine remains very relevant in malaria treatment in the tropics, and we therefore determined whether there is potential drug interaction between a Nigerian honey and quinine, a drug whose metabolism to 3-hydroxyquinine is mediated majorly by CYP3A4.
In a three-phase randomized crossover study with a washout period of 2 weeks between each treatment phase, ten (10) healthy volunteers received quinine sulphate tablet (600 mg single dose) alone (phase 1) or after administration of 10 ml of honey (Phase 2) and 20 mL of honey (Phase 3) twice daily for seven (7) days. Blood samples were collected at the 16th hour post-quinine administration in each phase, and quinine and its major metabolite, 3-hydroxyquinine, were analysed using a validated HPLC method.
After scheduled doses of honey, the mean metabolic ratios of quinine (3-hydroxyquinine/quinine) increased by 24·4% (with 10 mL of honey) and reduced by 23·9% (with 20 mL of honey) when compared to baseline. These magnitudes of alteration in the mean metabolic ratios were not significant (P > 0·05; Friedman test). The geometric mean (95% CI) for the metabolic ratio of quinine before and after honey intake at the two dose levels studied was 0·82 (0·54, 1·23) and 1·29 (0·96, 1·72), respectively, and were also not significant (P = 0·296 and 0·081 respectively; Student's t-test).
This is a pioneer study on the effect of Nigerian/African honey on quinine metabolism. The findings indicated that low and high doses of honey did not significantly affect metabolism of quinine to 3-hydroxyquinine. This suggests that CYP3A4 activity is not significantly altered following low or high dose of honey, as CYP3A4 has been reported to be responsible for the conversion of quinine to 3-hydroxyquinine. In conclusion, the outcome of this study suggests that there may be no potential significant metabolic interaction between Nigerian honey and quinine administration.
一些研究(尽管报告结果相互矛盾)表明,食用蜂蜜有可能调节药物代谢酶,这可能导致蜂蜜与药物之间的相互作用。大量研究表明,蜂蜜的成分会因主要的花卉、加工和环境因素而有所不同。因此,蜂蜜成分的差异可能是导致所得出的有争议结果的一个因素。此前尚未对来自非洲的任何蜂蜜进行过药物相互作用研究。CYP 3A4是药物代谢研究中的一种重要酶,因为它参与了超过50%临床使用药物的代谢,而奎宁在热带地区的疟疾治疗中仍然非常重要,因此我们确定了尼日利亚蜂蜜与奎宁之间是否存在潜在的药物相互作用,奎宁代谢为3-羟基奎宁主要由CYP3A4介导。
在一项三相随机交叉研究中,每个治疗阶段之间有2周的洗脱期,十名健康志愿者单独服用硫酸奎宁片(单次剂量600毫克)(第1阶段),或在每天服用10毫升蜂蜜(第2阶段)和20毫升蜂蜜(第3阶段),持续7天后服用(第2阶段和第3阶段)。在每个阶段奎宁给药后第16小时采集血样,使用经过验证的高效液相色谱法分析奎宁及其主要代谢物3-羟基奎宁。
在按计划服用蜂蜜剂量后,与基线相比,奎宁的平均代谢率(3-羟基奎宁/奎宁)在服用10毫升蜂蜜时增加了24.4%,在服用20毫升蜂蜜时降低了23.9%。这些平均代谢率变化的幅度不显著(P>0.05;弗里德曼检验)。在研究的两个剂量水平下,服用蜂蜜前后奎宁代谢率的几何平均值(95%置信区间)分别为0.82(0.54,1.23)和1.29(0.96,1.72),也不显著(分别为P = 0.296和0.081;学生t检验)。
这是一项关于尼日利亚/非洲蜂蜜对奎宁代谢影响的开创性研究。研究结果表明,低剂量和高剂量的蜂蜜均未显著影响奎宁代谢为3-羟基奎宁的过程。这表明低剂量或高剂量蜂蜜后CYP3A4活性没有显著改变,因为据报道CYP3A4负责将奎宁转化为3-羟基奎宁。总之,这项研究的结果表明,尼日利亚蜂蜜与奎宁给药之间可能不存在潜在的显著代谢相互作用。